Nobody has announced a retatrutide price, Lilly included. So here is my estimate: $450 to $650 a month at launch if you pay cash, most likely near $550, and lower within a couple of years after that. It is a guess, but not a blind one.
I bought Zepbound with my own money for months, after my insurance denied it and before it changed its mind. So I have paid Lilly’s cash price myself.
Disclosure up front: I own Eli Lilly stock and I take Zepbound, a Lilly drug.
| Retatrutide status | |
|---|---|
| FDA approved | No |
| FDA application | Planned Q1 2027 (Lilly intends to file it as a biologic; the FDA calls it a drug) |
| Brand name | Not announced |
| Last checked | September 4, 2026 |
How much will retatrutide cost per month?
The anchor is not what Zepbound costs now, but what it cost on day one.
When Zepbound arrived in November 2023, Lilly’s launch release put it at “as low as $550” a month for people whose insurance would not cover it. The same release published a list price of $1,059.87. Ignore it. Almost nobody pays list; it exists to be negotiated down. What matters is the cash price, and on day one that was $550.
Retatrutide should land above today’s Zepbound, which runs $299 to $449. It is the better drug, and it is new. That is the floor.
| Drug | Self-pay price per month |
|---|---|
| Foundayo (orforglipron), Lilly’s pill | $149 to $299 by dose |
| Zepbound KwikPen or vial | $299 to $449 by dose |
| Wegovy pen (Novo, for contrast) | $349 to $399 by dose |
Self-pay prices checked September 4, 2026 on LillyDirect, Foundayo’s terms and NovoCare. Wegovy’s first two fills are $199 for new patients. Both companies’ self-pay prices run through December 31, 2026.
The ceiling is competition. Most of those prices are Lilly’s own, so a $900 drug mainly moves people to Zepbound. Novo’s CagriSema has a US decision expected in late 2026 and will probably be selling before retatrutide is filed. And a $2,000 price leaves most of the people buying retatrutide as a research chemical where they are. Lilly has sued six sellers and flagged more than 14,000 websites, and that market has not gone away.
Floor and ceiling give the band, and the middle sits near $550, because that is what Lilly charged on day one last time. The rough version: roughly half again what Zepbound costs today, and lower if Zepbound falls first.
These prices also fall: Zepbound’s cash price is well below its own launch number, and Foundayo arrived at $149. Whatever retatrutide launches at, I expect it lower by 2030.
The way I am most likely wrong is the opposite of cheap: Lilly could treat the extra weight loss as a premium feature and charge a smaller group more, without needing anyone to switch off Zepbound. CagriSema’s price will show that first.
Get the next one in your inbox
I cover the latest GLP-1 trials and access changes weekly. Free, no spam, unsubscribe whenever.
Is retatrutide worth the money?
Probably not, if Zepbound is working for you.
Retatrutide has produced greater average weight loss. Its Phase 3 obesity trial reported 28.3 percent at the top dose; SURMOUNT-1 reported 20.9 percent on 15 mg of tirzepatide. You cannot subtract one from the other, because the trials count weight loss under different statistical rules; lined up the same way the gap is four to six points. The head-to-head, TRIUMPH-5, has not reported.
Retatrutide also produced a dose-related burning or tingling skin sensation in 4.5 to 7.3 percent of people, against about one percent on placebo.
The dose ladder is the interesting part. The lowest dose Lilly tested, 4 mg, is reached with one escalation step and lost 19.0 percent, with fewer people quitting over side effects than quit placebo. If the entry dose does roughly what Zepbound’s top dose does, most people never climb, and Lilly cannot build a price ladder on titration the way it did with Zepbound.
The people with the clearest reason to wait are the ones who stalled on tirzepatide or could not tolerate it. If you are losing weight on Zepbound, holding out for a drug two years away and unpriced is a bad trade. I compared the two in retatrutide vs Zepbound.
Retatrutide cost without insurance
The drug is only part of the bill. Your own doctor sending a script to a direct pharmacy runs roughly $27 to $108 a year in copays. Hims, Ro and LifeMD charge $39 the first month then $149, medication not included, or $1,678 in year one. Same drug, about sixty times as much for the prescription, and a new molecule changes none of it. I priced that market in what to do when insurance won’t cover your GLP-1.
Retatrutide cost with insurance
Will insurance cover retatrutide? There is no formulary tier and no prior-authorization form for it yet.
On a commercial plan, ask why a payer already covering Zepbound would pay more for a drug that does roughly the same job for most people. I do not think most of them will, at least not first. Expect to fail tirzepatide before anyone approves retatrutide, which makes it a cash drug for most of the people who want it. My own plan denied Zepbound and covered it months later, so a denial is not always permanent.
Medicare is harder, and the timing is bad. The way in today is the CMS GLP-1 Bridge, a demonstration outside normal Part D that costs a flat $50 a month and covers Foundayo, Wegovy and the Zepbound KwikPen. It expires December 31, 2027, and retatrutide will probably not be approved before it does. Ordinary Part D is the other route, and plans can add drugs mid-year, so the common claim that you must wait until January is wrong.
When will retatrutide be available?
Not in 2026, and probably not in 2027 either. Lilly said in its second-quarter results that the trial package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, and that it plans to file with the FDA in the first quarter of 2027. A standard review runs about a year from submission, which points at 2028. A priority review would pull it into late 2027, and Lilly has not announced one.
There is also a fight over what retatrutide legally is. The FDA calls it a drug, worth five years of exclusivity; Lilly is suing to have it called a biologic, worth twelve, and the Seventh Circuit hears argument on September 24, 2026. For a buyer it barely matters this decade: even five years runs past 2033 once the clock starts. I wrote that fight up in my Zepbound will go generic, and Lilly is in court to make sure retatrutide doesn’t.
So: $450 to $650 a month at launch, most likely near $550, and I would bet the first complaints are about prior authorization, not the price. I keep the GLP-1 pipeline tracker current, and this page gets rewritten the day Lilly announces a number.
Disclosure: I own Eli Lilly stock, the only pharmaceutical stock I hold, and this page discusses Lilly products and forecasts Lilly’s pricing behaviour. I take Zepbound, a Lilly drug. I have no affiliate relationship with any company named here and nobody paid for this page. Nothing here is medical advice, and no drug decision should be made on a price table.